Benzinga | Mar 30, 2021 07:02AM EDT

OraSure Technologies Submits COVID-19 Rapid Antigen Prescription Home Self-Test And Professional Test To FDA For Emergency Use Authorization

OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its COVID-19 rapid antigen test for both Prescription Home Use, and Professional Use in point of care (POC) settings.